William Blair News
Keep up to date on our recent transactions, announcements, and events.
News and Events
-
-
-
-
-
-
Aardvark Therapeutics, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Aardvark Therapeutics, Inc. (AARD $13.98). Aardvark is advancing ARD-101, an oral therapy that targets bitter taste receptors (TAS2Rs) in the gastrointestinal tract, and ARD-201, a combination of ARD-101 and a DPP-4 inhibitor, for treating Prader-Willi syndrome (PWS) and obesity, respectively.
-
Awards and Recognition
In The Media
-
-
Michael Patchen Published in Institutional Asset Manager
William Blair Investment Management global equity research analyst Michael Patchen was published in Institutional Asset Manager, stemming from his article on how the current geopolitical landscape has shifted how the EU and its member states need to think about defense spending.
-
The Wall Street Journal Turns to Dylan Carden for Commentary on TJ Maxx
William Blair research analyst Dylan Carden was quoted in The Wall Street Journal’s coverage of the forecast from T.J. Maxx’s parent company, TJX, for holiday 2025 and how it continues to lure budget-conscious to its brands, which also include Marshalls and Home Goods.
-
Sharon Zackfia Highlights Impact of Millennials, Gen Z on Cruise Industry for the Financial Times
William Blair research analyst Sharon Zackfia was quoted in the Financial Times’ coverage of how millennials and Gen Z consumers are having a significant impact on the cruise sector after the COVID-19 pandemic slowed the industry to a crawl.
-
Contact Us
Please contact Padraic Swanton with any media-related inquiries or to request a complete media kit.
+1 312 364 5290
pswanton@williamblair.com
For inquiries related to Equity Research, please contact Chris Thonis.
+1 312 364 8565
cthonis@williamblair.com
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights